EMA Authorised: Bilprevda (denosumab) — Sciencepharma Sp. z o.o

View source ↗

Summary

The EMA authorised Bilprevda (denosumab) from Sciencepharma Sp. z o.o. for Giant Cell Tumor of Bone. This expands denosumab's use to bone neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Neoplasms
• Giant Cell Tumor of Bone

Drugs mentioned

• BILPREVDA (DENOSUMAB)

Snippet

Status: Authorised. Therapeutic area: Giant Cell Tumor of Bone;Neoplasms, Bone Tissue. MAH: Sciencepharma Sp. z o.o. Decision date: 08/01/2026